Hut 8 price target raised to $35 from $26 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Hut 8 (HUT) to $35 from $26 and keeps a Buy rating on the shares. The company reported ...
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop
Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...
Yahoo Finance18h
Opus Genetics reinstated with a Buy at H.C. Wainwright
H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes ...
Instil Bio price target lowered to $110 from $120 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 ...
bovnews8h
Lexicon Pharmaceuticals Inc (LXRX) Stock Sees Market Value Hit $394.03 million: What Are the Implications?
On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...
MARA Holdings Faces Mixed Analyst Sentiment: Revenue Miss And Conservative Forecasts Amid Bitcoin Rally
MARA shares down as Q3 earnings miss estimates with lower revenue and adjusted loss, analysts maintain mixed views and price ...
Nasdaq22d
Ocuphire Pharma rating placed under review at H.C. Wainwright
H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. The views and opinions expressed herein are the ...
H.C. Wainwright Reaffirms Their Hold Rating on Bolt Biotherapeutics (BOLT)
In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report).